Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | GNRHR | P30968 | 16/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | FABP4 | P15090 | 1/20 | 0.38 |
| ▸ | STIM1 | Q13586 | 1/20 | 0.36 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL124962 | 0.89 | ALDH1A1 (0.51) | ALDH1A1HPGDGNRHR | |
| SCHEMBL23110398 | 0.88 | HPGD (0.41) | HPGDTSHRHSD17B10GNRHRCYP3A4 | |
| SCHEMBL23193855 | 0.87 | ALDH1A1 (0.44) | ALDH1A1HPGDTSHRHSD17B10GNRHR | |
| SCHEMBL1642571 | 0.86 | HPGD (0.39) | HPGDTSHRHSD17B10GNRHRCYP3A4 | |
| SCHEMBL12648510 | 0.86 | GNRHR (0.40) | HPGDTSHRHSD17B10GNRHRCYP3A4 | |
| SCHEMBL23595084 | 0.85 | FABP4 (0.37) | HPGDTSHRHSD17B10GNRHRCYP3A4 | |
| SCHEMBL4027176 | 0.83 | PKM (0.47) | ALDH1A1GNRHR | |
| SCHEMBL22702886 | 0.81 | HPGD (0.41) | HPGDTSHRHSD17B10GNRHRCYP3A4 | |
| SCHEMBL7644570 | 0.80 | ALDH1A1 (0.44) | ALDH1A1HPGDTSHRGNRHRCYP3A4 | |
| SCHEMBL1739351 | 0.79 | GNRHR (0.46) | GNRHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114641468-B | Process for synthesizing ELAGOLIX sodium salt and intermediate of said process | 工业化学有限公司 | 2024-11-12 | — | — | CN | claimed |
| US-20230072265-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF 4-({(1 R)-2-[5-(2-FLUORO-3METHOXYPHENYL)-3-{[2-FLUORO-6-(TRIFLUORO METHYL) PHENYL]METHYL}-4-METHYL-2,6-DIOXO-3,6DIHYDROPYRIMIDIN-1(2 H)-YL]-1-PHENYLETHYL}AMINO)BUTANOIC ACID OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS | MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) | 2023-03-09 | — | — | US | claimed |
| CN-114641468-A | Process for the synthesis of the sodium salt of 4- [ [ (1R) -2- [5- (2-fluoro-3-methoxyphenyl) -3- [ [ 2-fluoro-6- (trifluoromethyl) -phenyl ] methyl ] -3, 6-dihydro-4-methyl-2, 6-dioxo-1 (2H) -pyrimidinyl ] -1-phenylethyl ] amino ] -butyric acid (ELAGOLIX sodium salt) and intermediates of said process | 工业化学有限公司 | 2022-06-17 | — | — | CN | claimed |
| WO-2021130776-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF 4-({(1 R)-2-[5-(2-FLUORO-3METHOXYPHENYL)-3-{[2-FLUORO-6-(TRIFLUORO METHYL) PHENYL]METHYL}-4-METHYL-2,6-DIOXO-3,6DIHYDROPYRIMIDIN-1(2 H)-YL]-1-PHENYLETHYL}AMINO)BUTANOIC ACID OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS | MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) | 2021-07-01 | — | — | WO | claimed |
| CN-116283797-B | Synthesis method of oxaagoli sodium | 浙江车头制药股份有限公司 | 2024-11-29 | — | — | CN | disclosed |
| CN-114641468-B | Process for synthesizing ELAGOLIX sodium salt and intermediate of said process | 工业化学有限公司 | 2024-11-12 | — | — | CN | disclosed |
| US-11858901-B2 | 3-((R)-2-(amino-2-phenylethyl)-1-(2-fluoro-6 trifluoromethyl benzyl)-5-iodo-6-methyl-1H-pyrimidine-2,4-dione or a salt thereof, process for its preparation, and its use in the synthesis of elagolix | MOEHS IBERICA, S.L. (ES) | 2024-01-02 | — | — | US | disclosed |
| US-11858901-B2 | 3-((R)-2-(amino-2-phenylethyl)-1-(2-fluoro-6 trifluoromethyl benzyl)-5-iodo-6-methyl-1H-pyrimidine-2,4-dione or a salt thereof, process for its preparation, and its use in the synthesis of elagolix | MOEHS IBERICA, S.L. (ES) | 2024-01-02 | — | — | US | disclosed |
| US-11840519-B2 | Process for the synthesis of the sodium salt of 4-[[(1R)-2-[5-(2-fluoro-3-methoxyphenyl)-3-[[2-fluoro-6-(trifluoromethyl)-phenyl]methyl]-3,6-dihydro-4-methyl-2.6-dioxo-1(2H)-pyrimidinyl]-1-phenylethyl]amino]-butanoic acid (elagolix sodium salt) and intermediates of said process | INDUSTRIALE CHIMICA S.R.L. (IT) | 2023-12-12 | — | — | US | disclosed |
| US-11840519-B2 | Process for the synthesis of the sodium salt of 4-[[(1R)-2-[5-(2-fluoro-3-methoxyphenyl)-3-[[2-fluoro-6-(trifluoromethyl)-phenyl]methyl]-3,6-dihydro-4-methyl-2.6-dioxo-1(2H)-pyrimidinyl]-1-phenylethyl]amino]-butanoic acid (elagolix sodium salt) and intermediates of said process | INDUSTRIALE CHIMICA S.R.L. (IT) | 2023-12-12 | — | — | US | disclosed |
| CN-116283797-A | Synthesis method of oxaagoli sodium | 浙江车头制药股份有限公司 | 2023-06-23 | — | — | CN | disclosed |
| US-20230144828-A1 | GONADOTROPIN RELEASING HORMONE RECEPTOR ANTAGONIST AND USE THEREOF | SHANGHAI INNOFORTUNE BOITECH CO. LTD. (CN) | 2023-05-11 | — | — | US | disclosed |
| US-20080262005-A1 | Uracil-Type Gonadotropin-Releasing Hormone Receptor Antagonists and Methods Related Thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080262005-A1 | Uracil-Type Gonadotropin-Releasing Hormone Receptor Antagonists and Methods Related Thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080262005-A1 | Uracil-Type Gonadotropin-Releasing Hormone Receptor Antagonists and Methods Related Thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| US-7419983-B2 | e.g. 3-[{hydroxycarbonylpropyl-amino}-2-phenylethyl]-5-(2-fluoro-3-methoxyphenyl)-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methylpyrimidine-2,4(1H,3H)-dione; sex-hormone related diseases; anticarcinogenic agent; endometriosis, uterine fibroids, polycystic ovarian disease | NEUROCRINE BIOSCIENCES, INC. (US) | 2008-09-02 | — | — | US | disclosed |
| US-20070191403-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. (US) | 2007-08-16 | — | — | US | disclosed |
| EP-1660091-A1 | PYRIMIDINE-2,4-DIONE DERIVATIVES AS GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS | NEUROCRINE BIOSCIENCES, INC. (US) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005113516-A1 | URACIL-TYPE GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATED THERETO | NEUROCRINE BIOSCIENCES, INC. (US) | 2005-12-01 | — | — | WO | disclosed |
| WO-2005007164-A1 | PYRIMIDINE-2,4-DIONE DERIVATIVES AS GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS | NEUROCRINE BIOSCIENCES, INC. (US) | 2005-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191403-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | GNRHR, GHRHR, LHCGR | ALDH1A1 3158/4885HPGD 1158/4885TSHR 50/4885 |
| US-20080262005-A1 | Uracil-Type Gonadotropin-Releasing Hormone Receptor Antagonists and Methods Related Thereto | GNRHR, FSHR, GHRHR | ALDH1A1 2067/4885HPGD 1772/4885TSHR 42/4885 |
| US-11840519-B2 | Process for the synthesis of the sodium salt of 4-[[(1R)-2-[5-(2-fluoro-3-methoxyphenyl)-3-[[2-fluoro-6-(trifluoromethyl)-phenyl]methyl]-3,6-dihydro-4-methyl-2.6-dioxo-1(2H)-pyrimidinyl]-1-phenylethyl]amino]-butanoic acid (elagolix sodium salt) and intermediates of said process | ELP1, BPNT1, EPX | ALDH1A1 110/4885HPGD 3964/4885TSHR 3719/4885 |
| US-20230144828-A1 | GONADOTROPIN RELEASING HORMONE RECEPTOR ANTAGONIST AND USE THEREOF | GNRHR, GHRHR, LHCGR | ALDH1A1 4081/4885HPGD 2544/4885TSHR 318/4885 |
| US-11858901-B2 | 3-((R)-2-(amino-2-phenylethyl)-1-(2-fluoro-6 trifluoromethyl benzyl)-5-iodo-6-methyl-1H-pyrimidine-2,4-dione or a salt thereof, process for its preparation, and its use in the synthesis of elagolix | JAK2, EML4, AZI2 | ALDH1A1 1234/4885HPGD 4848/4885TSHR 517/4885 |
| US-20230072265-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF 4-({(1 R)-2-[5-(2-FLUORO-3METHOXYPHENYL)-3-{[2-FLUORO-6-(TRIFLUORO METHYL) PHENYL]METHYL}-4-METHYL-2,6-DIOXO-3,6DIHYDROPYRIMIDIN-1(2 H)-YL]-1-PHENYLETHYL}AMINO)BUTANOIC ACID OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS | BPNT1, GABRA6, GABRA1 | ALDH1A1 31/4885HPGD 2311/4885TSHR 3072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.